EU must take the lead to ensure security of supply for medicines

16 June 2021

Legislative reforms aligned with current off-patent market conditions are the […]

Open borders that prioritise essential goods key to medicines supply in Europe

2 June 2021

EU Industrial strategy should be key to improving medicines supply chains

17 May 2021

The newly launched update of the industrial strategy aims to […]

“Off patent medicines essential for a fairer, healthier, and sustainable Europe” says President Christoph Stoller

30 April 2021

Christoph Stoller will speak at 3A CONFERENCE – Availability, Accessibility, […]

European patients need improved access to biosimilar medicines

22 April 2021

Fifteen years after the first global approval, biosimilar medicines systemically […]

New report assesses progress on biosimilar medicine policies across Europe

29 March 2021

Biosimilar medicines are increasingly relevant to public health as emphasised by the […]

A new medicines trade and health security agenda for the European Commission

19 February 2021

In response to the European Commission Trade Communication published on […]

No further excuse to delay digital regulatory infrastructure for medicines after Covid-19 pandemic

19 February 2021

Smarter use of generic, biosimilar and value added medicines will ensure equitable access to cancer care

4 February 2021

AESGP, EFPIA and Medicines for Europe reflections on the European Medicines Agency, the Heads of Medicines Agencies and the European Commission “Key principles for the use of electronic product information for EU medicines” press release.

3 February 2021